This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of economic evaluation
 Cost-utility analysis 
Study objective
This study examined the cost-effectiveness of new protease inhibitors, added to standard therapy, and of an interleukin-28B genotyping assay to select patients for standard or triple therapy, for the treatment of chronic hepatitis C virus.
Interventions
Three strategies were examined: standard therapy; triple therapy of standard therapy and a new protease inhibitor; and interleukin-28B genotyping to assign patients to treatment, with those with non-CC genotypes given triple therapy and those with CC genotypes given standard therapy.
Standard therapy was 150 micrograms once weekly of pegylated interferon alpha-2b (or 180 micrograms of pegylated interferon alpha-2a) plus 1g daily of ribavirin. Triple therapy included boceprevir as the protease inhibitor.
Location/setting
USA/secondary care.
Methods

Analytical approach:
The analysis was based on a Markov model, with a lifetime horizon. The interleukin-28B genotype (CC or non-CC) was a key factor to define the patient cohort. Two main scenarios were considered (for mild and advanced fibrosis). The authors stated that the study took the perspective of society.
Effectiveness data:
The treatment effect was the rate of sustained virological response (SVR) and this was the key input for the model. It was from two pivotal phase III trials for the new protease inhibitor and from an intention-to-treat analysis of cohorts for standard therapy. Race-and gender-specific data were used. Some estimates on mortality were from official life tables. Assumptions were made for treatment adherence.
Monetary benefit and utility valuations:
Most of the health-related quality-of-life weights were from the Medical Expenditure Panel Survey; some were from other published studies. Quality-adjusted life-years (QALYs) were the summary benefit measure and they were discounted at an annual rate of 3%.
Measure of benefit:
Cost data:
The economic analysis included the costs of drugs (including for adverse events), interleukin-28B testing, and annual health care depending on the stage of disease (including liver transplantation). Age-specific baseline health care costs included patients' out-of-pocket expenses. Drug costs were based on average wholesale prices, which were converted to best prices using a specific conversion factor consistent with Congressional Budget Office estimates. Annual medical care costs were based on medical claims data for chronic hepatitis C. All costs were in US $ and an annual discount rate of 3% was used. The price year was 2010.
Analysis of uncertainty:
Both deterministic and probabilistic sensitivity analyses were performed to investigate uncertainty around all the inputs to the model, using published and assumed ranges of values. An alternative protease inhibitor, telaprevir, was considered in a scenario analysis.
Results
In patients with mild fibrosis, the expected lifetime costs were $160,456 with standard therapy, $177,152 with testing, and $183,257 with triple therapy. The QALYs were 10.97 with standard therapy, 11.24 with testing, and 11.30 with triple therapy. An increase in the price of protease inhibitors increased the incremental cost-utility ratios, for example when using telaprevir instead of boceprevir. Variations in the side-effects did not substantially change the findings.
The probabilistic analysis showed that, for patients with advanced fibrosis, the likelihood of testing or triple therapy being cost-effective was 98% at a threshold of $50,000 per QALY or 100% at a threshold of $100,000 per QALY. For patients with mild fibrosis, the likelihood was 18% at $50,000 and 95% at $100,000 per QALY.
